9th International Science Congress (ISC-2019).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Human papillomavirus and its oncogenic role in cervical cancers in sexually active women

Author Affiliations

  • 1Department of Microbiology, Yenepoya Medical College, Mangalore, Karnataka, India
  • 2Department of Microbiology, Yenepoya Medical College, Mangalore, Karnataka, India

Int. Res. J. Biological Sci., Volume 6, Issue (4), Pages 40-47, April,10 (2017)


Human Papillomavirsus (HPV) are ubiquitous in nature. At present, approximately 120 distinct genotypes have been identified in humans. HPV infections cause a variety of benign proliferations: warts (genital and cutaneous), cervical intraepithelial neoplasias, anogenital papillomas, oro-pharyngeal papillomas, and other types of hyperkeratoses. Cervical cancer is the most common cause of cancer-related death in women worldwide. Infection with high-risk HPV is established as the cause of cervical carcinoma; therefore, high risk HPV detection may have prognostic significance for the women who are at increased risk of disease progression. The lack of data on the incidence of cervical cancer and the prevalent strains in India makes it difficult to determine disease burden. Identification and accurate genotyping of the virus in cervical specimens is important to inform intervention policies for future management of HPV associated disease. This study also focuses on the various risk factors associated with persistence of HPV infection leading to cervical cancer. Describing the frequency and nature of HPV persistence, by HPV type, is important to understand its clinical signi&


  1. Gomez D.T. and Santos J.L. (2007)., Human Papillomavirus infection and cervical cancer: Pathogenesis and Epidemiology., Communicating Current Research and Educational Topics and Trends in Applied Microbiology, A. Méndez-Vilas (Ed.), 680-688.
  2. Burd E.M. (2003)., Human Papillomavirus and Cervical Cancer., Clinical Microbiology Reviews, 16(1), 1-17.
  3. Hausen H.Z. (1996)., Papillomavirus infections - a major cause of human cancers., Biochimica et Biophysica Acta, 1288(2), 55-78.
  4. Moore P.S. and Chang Y. (2010)., Why do viruses cause cancer? Highlights of the first century of human tumour virology., Nature Reviews/ Cancer, 10(12), 878-889.
  5. Jia H., Wang X., Long Z. and Li L. (2015)., Human Papillomavirus infection and cervical dysplasia in female sex workers in Northeast China: an observational study., BMC Public Health, 15, 695,
  6. Joseph D.A., Miller J.W., Wu X., Chen V.W., Morris C.R., Goodman M.T., Villalon‐Gomez J.M., Williams M.A. and Cress R.D. (2008)., Understanding the Burden of Human Papillomavirus associated Anal Cancers in the US., Cancer, 113(10), 2892-2900.
  7. Schmeink C.E., Melchers W.J.G., Siebers A.G., Quint W.G.V., Massuger Leon F.A.G. and Bekkers R.L.M. (2011)., Human Papillomavirus Persistence in Young Unscreened Women, a Prospective Cohort Study., PLoS ONE., 6(11), e27937.
  8. Bell M.C., Grimminger D., Jacobsen C., Chauhan S.C., Maher D.M. and Buchwald D.S. (2011)., Risk Factors for HPV Infection among American Indian and White Women in the Northern Plains., Gynecology Oncology, 121(3), 532-536.
  9. Rositch A.F., Koshiol J., Hudgens M., Razzaghi H., Backes D.M., Pimenta J.M., Franco E.L., Poole C. and Smith J.S. (2013)., Patterns of Persistent Genital Human Papillomavirus Infection among Women Worldwide: A Literature Review and Meta-analysis., International Journal of Cancer, 133(6), 1271-1285.
  10. Rositch A.F., Soetersc H.M., Offutt-Powellc T.N., Wheelerc B.S., Taylor Sylvia M. and Smith J.S. (2014)., The incidence of Human papillomavirus infection following treatment for cervical neoplasia: A systematic review., Gynecology Oncology, 132(3), 767-779.
  11. Chase D.M., Osann K., Sepina N., Wenzel L. and Tewari K.S. (2012)., The Challenge of Follow-Up in a Low-Income Colposcopy Clinic: Characteristics Associated With Noncompliance in High-Risk Populations., Journal Lower Genital Tract Disease, 16(4), 345-351.
  12. Jahdi F., Khademi K., Khoei E.M., Haghani H. and Yarandi F. (2013)., Reproductive Factors Associated to Human Papillomavirus Infection in Iranian Woman., Journal of Family and Reproductive Health, 7(3), 145-149.
  13. Park Hyun, Lee Won Si, Lee In Ho, Ryu Hyun Mee, Cho A Reum, Kang Young Soon, Hong Sung Ran, Kim Sung Soon, Seong Seok Ju, Shin Son Moon and Kim Tae Jin (2012)., Rate of vertical transmission of human papillomavirus from mothers to infants: Relationship between infection rate and mode of delivery., Virology Journal., 9, 80.
  14. Faridi R., Zahra A., Khan K. and Idrees M. (2011)., Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer., Virology Journal, 8(1), 269.
  15. Parkin D.M., Bray F., Ferlay J. and Pisani P. (2005)., Global cancer statistics., CA Cancer J Clin., 55(2), 74-108.
  16. Nahar Q., Sultana F., Alam A., Islam J.Y., Rahman M., Khatun Fatema, Alam Nazmul, Dasgupta Sushil Kanta, Marions Lena, Kamal Mohammed, Cravioto Alejandro and Reichenbach Laura (2014)., Genital Human Papillomavirus Infection among Women in Bangladesh: Findings from a Population-Based Survey, . PLoS ONE., 9(10), e107675.
  17. Park S.J., Seo J., Ha S.H. and Jung G.W. (2014)., Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Male Genital Warts., Korean J Urology, 55(3), 207-212.
  18. Franceschi S., Rajkumar T., Vaccarella S., Gajalakshmi V., Sharmila A., Snijders P., MUnoz N., Meijer C. and Herrero R. (2003)., Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study., International Journal of Cancer, 107(1), 127-33.
  19. Sowjanya A.P., Jain M., Rani U., Padma S., Das M., Shah K.V., Rao B.N., Devi R.R., Gravitt P. and Ramakrishna G. (2005)., Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India., BMC Infectious Disease, 5(1), 116.
  20. Bhatla N., Dar L., Patro R.K.A., Kriplani A., Gulati A., Verma K., Broor S., Shah K. and Gravitt P.E. (2006)., Human papillomavirus type distribution in cervical cancer in Delhi, India., Int J Gynecol Pathol., 25(4), 398-402.
  21. Peedicayil A., Abraham P., Sathish N., John S., Shah K., Sridharan G. and Gravitt P. (2006)., Human papillomavirus genotypes associated with cervical neoplasia in India., Int J Gynecol Cancer, 16(4), 1591-1595.
  22. Gopalkrishna V., Hedau S., Kailash U. and Das B.C. (2000)., Human Papillomavirus type 16 in cancer of the uterine cervix in different geographical regions of India (PS011)., 18th International Papillomavirus Conference, Barcelona, 138.
  23. Schiffman M. and Castle P.E. (2005)., The promise of global cervical cancer prevention., N England J Med., 353(20), 2101-2104.
  24. Das B.C., Hussain S., Nasare V. and Bharadwaj M. (2008)., Prospects and prejudices of human papillomavirus vaccines in India., Vaccine, 26(22), 2669-2679.
  25. Srivastava S., Shahi U.P., Dibya A., Gupta S. and Roy J.K. (2014)., Distribution of HPV Genotypes and Involvement of Risk Factors in Cervical Lesions and Invasive Cervical Cancer: A Study in an Indian Population., IJMCM, Spring, 3(2), 61-73.
  26. Soto-De Leon S.C., Rio-Ospina L.D., Camargo M., Sanchez R., Moreno-Perez D.A., Pérez-Prados A., Patarroyo M.E. and Patarroyo M.A. (2014)., Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study., BMC Infectious Diseases, 14(1), 395.
  27. Shepherd J.P., Frampton G.K. and Harris P. (2011)., Interventions for encouraging sexual behaviours intended to prevent cervical cancer., Cochrane Database System Review, 4, CD001035.
  28. Chan P.K.S., Picconi M.A., Cheung T.H., Giovannelli L. and Park J.S. (2012)., Laboratory and clinical aspects of human papillomavirus testing., Critical Reviews in Clinical Laboratory Sciences, 49(4), 117-136.
  29. Feltkamp M.C., de Koning M.N., Bavinck J.N. and Ter Schegget J. (2008)., Beta papillomaviruses: innocent by standers or causes of skin cancer., J Clin Virology, 43(4), 353-360.
  30. Asgari M.M., Kiviat N.B., Critchlow C.W., Stern J.E., Argenyi Z.B., Raugi Gregory J., Berg Daniel, Odland Peter B., Hawes Stephen E. and de Villiers Ethel-Michele (2008)., Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals., J Invest Dermatol., 128(6), 1409-1417.
  31. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu Li, Zahurak Marianna L., Daniel Richard W., Viglione Michael, Symer David E., Shah Keerti V. and Sidransky David (2000)., Evidence for a Causal Association between Human Papillomavirus and a Subset of Head and Neck Cancers., Journal of the National Cancer Institute, 92(9), 709-720.
  32. Betiol J., Villa L.L. and Sichero L. (2013)., Impact of HPV infection on the development of head and neck cancer., Brazilian Journal of Medical and Biological Research, 46(3), 217-226.
  33. Bernard E., Salort M.P., Favre M., Heard I., Astagneau E.D., Guillemot Didier and Thiébaut Anne C.M. (2013)., Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies., BMC Infectious Diseases, 13(1), 373.
  34. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X. Muñoz, Shah Keerti V., Snijders Peter J.F. and Meijer Chris J.L.M. (2003)., Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer., The New England Journal of Medicine., 348(6), 518-527.
  35. Shaikh F., Sanehi P. and Rawal R. (2012)., Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV., Bioinformation., 8(13), 607-612.
  36. Nair S. and Pillai M.R. (2005)., Human papillomavirus and disease mechanisms: relevance to oral and cervical cancers., Oral Diseases, 11(6), 350-359.
  37. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C. and Castle P.E. (2011)., Human Papillomavirus Testing in the Prevention of Cervical Cancer., J Natl Cancer Inst., 103(5), 368-383.
  38. Klaes R., Woerner S.M., Ridder R., Wentzensen N., Duerst M., Lotz Beatrix, Melsheimer Peter, Doeberitz Magnus von Knebel and Schneider A. (1999)., Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes., Cancer Res., 59(24), 6132-6136.
  39. Boers A., Bosgraaf R.P., van Leeuwen R.W., Schuuring E., Heideman D.A.M., Massuger L.F.A.G., Verhoef V.M.J., Bulten J., Melchers W.J.G., Zee A.G.J. Van Der, Bekkers R.L.M. and Wisman G.B.A. (2014)., DNA methylation analysis in self-sampled brush material as a triage test in hr HPV-positive women., British Journal of Cancer, 111(6), 1095-1101.
  40. Ortiz A.P., Romaguera J., Pérez C., Otero Y., Salgado M.S., Méndez Keimari, Valle Yari, Costa Maria Da, Suarez Erick, Palefsky Joel and Tortolero-Luna Guillermo (2013)., Human papillomavirus infection in women in Puerto Rico: Agreement between physicians-versus self-collected anogenital specimens., J Low Genit Tract Dis., 17(2), 210.
  41. Gage J.C., Partridge E.E., Rausa A., Gravitt P.E., Wacholder S., Schiffman Mark, Scarinci Isabel and Castle Philip E. (2011)., Comparative Performance of Human Papillomavirus DNA Testing Using Novel Sample Collection Methods., Journal of Clinical Microbiology, 49 (12), 4185-4189.
  42. Roberts C.C., Swoyer R., Bryan J.T. and Taddeo F.J. (2011)., Comparison of Real-Time Multiplex Human Papillomavirus (HPV) PCR Assays with the Linear Array HPV Genotyping PCR Assay and Influence of DNA Extraction Method on HPV Detection., Journal of Clinical Microbiology, 49(5), 1899-1906.
  43. Schweizer J., Lu P.S., Mahoney C.W., Bergery M.B., Ho M., Ramasamy Valli, Silver Jon E., Bisht Arnima, Labiad Yassine, Peck Roger B., Lim Jeanette, Jeronimo Jose, Howard Roslyn, Gravitt Patti E. and Castle Philip E. (2010). Feasibility Study of a Human Papillomavirus E6 Oncoprotein Test for Diagnosis of Cervical Precancer and Cancer. Journal of Clinical Microbiology, 48(12), 4646- 4648., undefined, undefined
  44. Garolla A., Pizzol D., Vasoin F., Barzon L., Bertoldo A. and Foresta C. (2014)., Counseling Reduces HPV Persistence in Coinfected Couples., J Sex Med., 11(1), 127-135.
  45. Delere Y., Remschmidt C., Leuschner J., Schuster M., Fesenfeld M., Schneider Achim, Wichmann Ole and Kaufmann Andreas M. (2014)., Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross- sectional study via home-based self-sampling., BMC Infectious Diseases, 14, 87.
  46. Bosch F.X., Broker T.R., Forman D., Moscicki A.B. and Gillison M.L., John Doorbar, Peter L Stern, Margaret Stanley, Marc Arbyn, Mario Poljak, Jack Cuzick, Philip E Castle, John T Schiller, Lauri E Markowitz, William A Fisher, Karen Canfell, Lynette A Denny, Eduardo L Franco, Marc Steben, Mark A Kane, Mark Schiffman, Chris JLM Meijer, Rengaswamy Sankaranarayanan, Xavier Castellsagué, Jane J Kim, Maria Brotons, Laia Alemany, Ginesa Albero, Mireia Diaz and Silvia de Sanjosé (2013)., Comprehensive Control of Human Papillomavirus Infections and Related Diseases., Vaccine., 31(8), 1-31.
  47. Das B.C., Hussain S., Nasare V. and Bharadwaj M. (2008)., Prospects and prejudices of human papillomavirus vaccines in India., Vaccine, 26(22), 2669-2679.
  48. Hariri S., Dunne E., Saraiya M., Unger E. and Markowitz L. (2011)., Human papillomavirus., VPD Surveillance Manual, 5th Edition, 5, 1-11.
  49. Wilson L.E., Pawlita M., Castle P.E., Waterboer T. and Sahasrabuddhe V., Gravitt Patti E., Schiffman Mark and Wentzensen Nicolas (2013)., Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study., Int. J. Cancer., 133(9), 2172- 2181.
  50. Tiggelaar S.M., Lin M.J., Viscidi R.P., Ji J. and Smith J.S. (2012)., Age-Specific Human Papillomavirus Antibody and DNA Prevalence: A Global Review., J Adolescence Health, 50(2), 110-131.